後天性希少血液疾患治療市場- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年、治療別、適応疾患別、流通チャネル別、地域別、競合

後天性希少血液疾患治療の世界市場は、2022年に79億5,000万米ドルと評価され、2028年までのCAGRは7.80%で、予測期間中に目覚ましい成長が見込まれています。

後天性希少血液疾患とは、血液とその成分（赤血球、白血球、血小板など）に影響を及ぼし、遺伝性ではなく生涯のうちに後天的に発症する、希少でしばしば生命を脅かす病態の一群を包含する用語です。これらの血液疾患は、出生時に存在するわけでも、遺伝によって受け継がれるわけでもないです。多くの場合、様々な誘因や基礎的な健康状態により、一生の間に発症または後天的に発症します。後天性希少血液疾患の診断、治療、管理には、血液専門医や希少血液疾患の専門知識を有する他のヘルスケアプロバイダーによる専門的なケアが必要となることが多くあります。治療のアプローチには、輸血、免疫抑制療法、標的療法、場合によっては骨髄移植などが含まれます。

ゲノム学、免疫学、分子生物学を含む医学研究の継続的な進歩により、これらの疾患の病因に関する理解が深まっています。この知識は、標的療法や治療法の革新の発展を支えています。希少疾病用医薬品の指定によって提供される、市場独占権の拡大、税額控除、開発コストの削減などの規制上のインセンティブは、製薬会社が希少疾病の研究開発に投資することを後押ししています。患者支援団体や組織は、研究の推進、認知度の向上、治療法へのアクセス改善の提唱において極めて重要な役割を果たしています。彼らの努力は、後天性希少血液疾患の分野における進歩を加速させるのに役立っています。遺伝子治療、モノクローナル抗体、免疫調節剤などの新しい治療法の出現は、後天性希少血液疾患の治療選択肢の幅を広げています。診断技術やテクノロジーの進歩により、後天性希少血液疾患の診断はより正確でタイムリーなものとなっています。これにより、早期の介入と治療が可能になっています。

主な市場促進要因

医療研究の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の後天性希少血液疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別（遺伝子組換え因子製剤、免疫グロブリン輸注療法、活性化プロトロンビン複合体濃縮製剤、トロンボポエチン受容体作動薬、その他）
  • 適応疾患別（後天性無顆粒球症、後天性血友病、後天性フォンウィルブランド症候群、発作性夜間ヘモグロビン尿症（PNH）、骨髄異形成症候群、その他）
  • 流通チャネル別（病院薬局、小売薬局、その他）
  • 企業別（2022年）
• 市場マップ

第6章 アジア太平洋地域の後天性希少血液疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の後天性希少血液疾患治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の後天性希少血液疾患治療市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の後天性希少血液疾患治療市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 疾患適応症別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの後天性希少血液疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 疾患適応症別
  • 流通チャネル別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の後天性希少血液疾患治療市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

• Alexion Pharmaceuticals, Inc.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Amgen, Inc.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Celgene Corporation
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Eli Lilly and Company
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Sanofi SA
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• GlaxoSmithKline plc
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Cyclacel Pharmaceuticals Inc.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Onconova Therapeutics, Inc
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Incyte Corporation
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• CTI BioPharma Corp
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis

第17章 戦略的提言

第18章 調査会社・免責事項

Global Acquired Orphan Blood Diseases Therapeutics Market has valued at USD 7.95 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.80% through 2028. Acquired orphan blood diseases is a term that encompasses a group of rare and often life-threatening medical conditions that affect the blood and its components (e.g., red blood cells, white blood cells, platelets) and are not inherited but acquired during a person's lifetime. These blood diseases are not present at birth or inherited through genetics. Instead, they develop or are acquired during a person's life, often due to various triggers or underlying health conditions. Diagnosis, treatment, and management of acquired orphan blood diseases often require specialized care from hematologists or other healthcare providers with expertise in rare blood disorders. Treatment approaches may include blood transfusions, immunosuppressive therapies, targeted therapies, and, in some cases, bone marrow transplantation.

Ongoing advancements in medical research, including genomics, immunology, and molecular biology, have deepened our understanding of the pathogenesis of these diseases. This knowledge supports the development of targeted therapies and treatment innovations. Regulatory incentives provided by orphan drug designations, such as extended market exclusivity, tax credits, and reduced development costs, encourage pharmaceutical companies to invest in research and development for rare diseases. Patient advocacy groups and organizations play a pivotal role in driving research, raising awareness, and advocating for improved access to treatments. Their efforts help accelerate progress in the field of acquired orphan blood diseases. The emergence of novel treatment modalities, including gene therapies, monoclonal antibodies, and immunomodulatory agents, has expanded the range of therapeutic options available for acquired orphan blood diseases. Advances in diagnostic techniques and technologies have led to more accurate and timely diagnoses of acquired orphan blood diseases. This enables early intervention and treatment.

Key Market Drivers

Advancements in Medical Research

Medical research has deepened our understanding of the underlying mechanisms and pathophysiology of acquired orphan blood diseases. This knowledge helps identify novel therapeutic targets and pathways for intervention. Research efforts have led to the development of targeted therapies that address the specific molecular and cellular abnormalities associated with these diseases. Targeted treatments often offer better efficacy and safety profiles compared to traditional therapies. Research has contributed to the identification of biomarkers and genetic markers associated with these diseases. Biomarkers enable early diagnosis, disease monitoring, and personalized treatment approaches. Ongoing research supports drug discovery and development programs aimed at creating innovative and more effective therapeutics. This includes the development of monoclonal antibodies, gene therapies, and small molecule drugs. Advances in clinical trial design and methodology, including adaptive trials and innovative endpoints, facilitate the evaluation of potential therapies. Clinical trials are essential for assessing treatment safety and efficacy. Medical research has led to the creation of patient registries and databases for rare diseases. These registries facilitate data collection, epidemiological studies, and clinical trial recruitment.

Collaborative efforts among researchers and healthcare institutions on a global scale promote knowledge sharing and accelerate research progress. These collaborations can lead to the discovery of novel therapies. Research has advanced the concept of precision medicine, allowing for tailored treatment approaches based on individual patient characteristics, including genetics and biomarkers. The development of disease models, such as in vitro cell cultures and animal models, enables researchers to test potential therapies and gain insights into disease mechanisms. Research findings are disseminated through scientific publications and conferences, raising awareness among healthcare providers, patients, and pharmaceutical companies about potential therapeutic options. Medical research actively involves patients in clinical trials and research initiatives. Patient engagement helps ensure that treatments meet the needs and preferences of those affected by these rare diseases. Advances in research often inform regulatory agencies' understanding of rare diseases and their willingness to provide expedited pathways for orphan drug designations and approvals. This factor will help in the development of the Global Acquired Orphan Blood Diseases Therapeutics Market.

Emerging Therapies

Emerging therapies often represent innovative and groundbreaking approaches to treating acquired orphan blood diseases. These therapies may include gene therapies, monoclonal antibodies, cell-based therapies, and small molecule drugs designed to target specific disease mechanisms. Many emerging therapies are designed to be more effective than traditional treatments. They may offer improved disease management, symptom control, and overall outcomes for patients, which makes them highly desirable in the medical community. Some emerging therapies have the potential to modify the course of the disease, halt its progression, or even provide a cure. This transformative impact on patients' lives drives significant demand. Many emerging therapies are designed to be more targeted, which can lead to fewer side effects and a better safety profile compared to older treatments. This can improve patient compliance and overall quality of life. Emerging therapies often take a patient-centric approach, tailoring treatments to individual patients based on their genetic and molecular characteristics. This personalized medicine approach is highly appealing to both patients and healthcare providers. Regulatory agencies may expedite the approval process for emerging therapies, recognizing their potential to address unmet medical needs in rare diseases. This accelerates their availability in the market.

The introduction of novel therapies can expand the overall market for acquired orphan blood disease therapeutics as more healthcare providers and patients seek these cutting-edge treatments. The promise of emerging therapies attracts increased investment from pharmaceutical companies and biotechnology firms. This investment drives research and development efforts in the field. Patients and advocacy groups often advocate for access to emerging therapies that can offer better outcomes and quality of life. Their advocacy contributes to the demand for these treatments. As emerging therapies demonstrate their effectiveness, healthcare providers are more likely to adopt them into their treatment protocols, further driving demand. Emerging therapies can lead to better disease management and reduced complications, resulting in cost savings for healthcare systems in the long run. The presence of emerging therapies in the market fosters competition among pharmaceutical companies. This competition can lead to price considerations and potentially more accessible treatment options. This factor will pace up the demand of the Global Acquired Orphan Blood Diseases Therapeutics Market.

Rising Demand of Orphan Drug Designations

Orphan drug designations provide pharmaceutical companies with various incentives, such as extended market exclusivity, tax credits, and research grants. These incentives make it more attractive for companies to invest in the research and development of treatments for rare diseases, including acquired orphan blood diseases. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), often offer expedited review and approval processes for orphan drugs. This accelerates the development timeline, allowing promising therapies to reach the market more quickly. Orphan drug designations typically grant a period of market exclusivity during which competing treatments cannot enter the market for the same indication. This exclusivity provides a competitive advantage and encourages pharmaceutical companies to pursue orphan drug development. Tax credits and reduced regulatory fees for orphan drugs can significantly lower the overall cost of drug development. This financial support makes it more financially viable for companies to invest in rare disease therapeutics.

Regulatory incentives often lead to quicker approvals and reduced regulatory burdens, facilitating easier market access for orphan drugs. Healthcare providers and patients can access these therapies sooner, increasing demand. Orphan drug designations attract increased research efforts into acquired orphan blood diseases. This expanded research not only helps identify potential therapies but also raises awareness about these rare conditions. Patient advocacy groups and organizations dedicated to rare diseases actively promote the benefits of orphan drug designations. They advocate for increased funding, research, and access to orphan drugs, contributing to demand. The availability of orphan drugs encourages healthcare providers to improve diagnostic capabilities, leading to earlier and more accurate diagnoses of acquired orphan blood diseases. Timely diagnosis drives the demand for effective therapies. Regulatory agencies worldwide have implemented orphan drug programs and designations, leading to greater international collaboration in rare disease research and development. This harmonization streamlines the path to market for orphan drugs. As more orphan drugs receive designations and approvals, the market for acquired orphan blood disease therapeutics expands. The availability of multiple treatment options contributes to market growth. The prospect of orphan drug designations attracts increased investment from both pharmaceutical companies and venture capitalists. This influx of funding accelerates research and development efforts. Effective orphan drugs can significantly enhance the quality of life for patients with acquired orphan blood diseases. This improvement in patient outcomes drives demand for these treatments. This factor will accelerate the demand of the Global Acquired Orphan Blood Diseases Therapeutics Market.

Key Market Challenges

Access to Treatment

Rare diseases, including acquired orphan blood diseases, often have a limited number of treatment options available due to their low prevalence. This scarcity of therapies can make it difficult for patients to access appropriate treatments. Many orphan drugs and emerging therapies are associated with high treatment costs. The rarity of these diseases and the costs of research and development often result in expensive therapies, making them financially burdensome for patients and healthcare systems. Acquired orphan blood diseases are not always well-known among healthcare providers and the public. This lack of awareness can lead to delayed diagnoses and difficulty in accessing specialized treatments. Access to advanced medical treatments can vary significantly based on geographic location. Patients in remote or underserved areas may face challenges in accessing specialized healthcare facilities and therapies. In some regions, the healthcare infrastructure may not be adequately equipped to diagnose and manage acquired orphan blood diseases. This can lead to delays in treatment initiation. The availability and extent of insurance coverage for orphan blood disease therapies can vary widely. In some cases, insurance plans may not fully cover the cost of treatment, leaving patients with high out-of-pocket expenses. Pharmaceutical companies may encounter challenges in obtaining reimbursement approvals for orphan drugs, leading to delays in patients' access to treatment. Specialized treatment centers and healthcare providers with expertise in acquired orphan blood diseases may be concentrated in urban areas, making it challenging for patients in rural regions to access care.

Economic and Pricing Pressures

Developing treatments for acquired orphan blood diseases can be exceptionally costly due to the limited patient population, complex research requirements, and the need for specialized therapies. These high development costs can put pressure on pharmaceutical companies to recoup their investments through pricing. The small number of patients with acquired orphan blood diseases means that pharmaceutical companies have a smaller market to target. To make their treatments financially viable, they may need to set higher prices per patient. Pricing for orphan drugs is often scrutinized for transparency, and the public and healthcare providers may question the justification for high drug prices, particularly when the cost-benefit ratio is unclear. Patients and healthcare providers may face challenges in obtaining insurance coverage for expensive orphan drugs. Insurers may hesitate to cover these therapies due to their high cost, leaving patients with significant out-of-pocket expenses. High drug prices can create barriers to access for patients who cannot afford the cost of treatment, potentially limiting their ability to benefit from lifesaving or life-improving therapies. Healthcare systems and payers often have budget constraints, and the introduction of costly orphan drugs can strain healthcare budgets. This can lead to challenges in negotiating pricing agreements with pharmaceutical companies. Economic disparities within and between countries can affect patients' access to orphan drugs. Patients in wealthier regions or countries may have better access, while those in poor areas may struggle to obtain treatment.

Key Market Trends

Expanded Access Programs

(Expanded access programs) EAPs prioritize the needs of patients who have limited or no alternative treatment options. These programs provide access to potentially life-saving therapies, reflecting a patient-centered approach to healthcare. EAPs allow patients to access investigational or emerging therapies that are still in the clinical trial or regulatory approval phases. This can be especially valuable for patients with rare and life-threatening diseases like acquired orphan blood diseases. EAPs are driven by ethical considerations, recognizing the urgency of providing treatments to patients who may not qualify for clinical trials or cannot wait for regulatory approvals. They provide hope and potential benefits to those in need. Patients who do not respond to standard therapies or who have contraindications to traditional treatments may find EAPs as a viable option for accessing novel treatments tailored to their specific condition. EAPs allow for the collection of real-world data and evidence regarding the safety and efficacy of therapies in diverse patient populations. This information can complement clinical trial data and inform treatment decisions. EAPs involve close collaboration between physicians, patients, pharmaceutical companies, and regulatory authorities. This collaboration ensures that patients receive the most appropriate and personalized care.

Segmental Insights

Therapy Insights

In 2022, the Global Acquired Orphan Blood Diseases Therapeutics Market largest share was held by Immunoglobulin Infusion Therapy segment and is predicted to continue expanding over the coming years. Immunoglobulin infusion therapy is a versatile treatment option used for a wide range of acquired orphan blood diseases, including immune thrombocytopenia (ITP), acquired hemophilia, and paroxysmal nocturnal hemoglobinuria (PNH), among others. This broad application makes it a common therapeutic choice for multiple conditions. Immunoglobulin therapy works by modulating the immune system, which is often a key factor in the pathogenesis of acquired orphan blood diseases. It can help regulate autoantibody production and reduce the immune response against self-components, providing a treatment option for autoimmune-based blood disorders. Some acquired orphan blood diseases, such as acquired hemophilia and severe ITP, can lead to life-threatening bleeding episodes. Immunoglobulin infusion therapy can be administered as an emergency treatment to control bleeding, making it a critical option in such situations.

Disease Indication Insights

In 2022, the Global Acquired Orphan Blood Diseases Therapeutics Market largest share was held by Acquired Hemophilia segment and is predicted to continue expanding over the coming years. Acquired hemophilia is a rare and potentially life-threatening bleeding disorder characterized by the development of autoantibodies against clotting factors, particularly factor VIII. While it is a rare condition, its incidence is relatively higher compared to some other acquired orphan blood diseases, which may contribute to its larger share of the market. Acquired hemophilia can present with severe and spontaneous bleeding episodes, which can be life-threatening. This clinical severity necessitates prompt diagnosis and treatment, leading to a higher demand for therapeutics. Advances in diagnostic methods and increased awareness of acquired hemophilia have led to earlier and more accurate diagnoses. This, in turn, has driven the demand for therapeutic interventions. The treatment of acquired hemophilia can be complex and may require a combination of therapies, including factor replacement, immunosuppressive drugs, and supportive care. These multiple treatment modalities contribute to a larger market share.

Distribution Channel Insights

In 2022, the Global Acquired Orphan Blood Diseases Therapeutics Market largest share was held by Hospital Pharmacy segment in the forecast period and is predicted to continue expanding over the coming years. Hospitals often have specialized departments and centers dedicated to the treatment of rare and complex diseases, including acquired orphan blood diseases. These centers have the expertise, equipment, and infrastructure to diagnose, manage, and treat these conditions effectively. Hospitals typically employ a multidisciplinary team of healthcare professionals, including hematologists, oncologists, pharmacists, and nurses, who are experienced in managing acquired orphan blood diseases. This expertise is critical for diagnosing and providing comprehensive care to patients. Hospitals often serve as primary sites for conducting clinical trials and research studies on orphan blood disease therapeutics. Clinical trials are essential for evaluating the safety and efficacy of new treatments, and hospitals have the resources to facilitate these trials. Acquired orphan blood diseases, especially those associated with bleeding or thrombosis, may require emergency care and interventions. Hospitals are equipped to provide immediate medical attention and critical care when needed.

Regional Insights

The North America region dominates the Global Acquired Orphan Blood Diseases Therapeutics Market in 2022. North America, particularly the United States, is a global hub for pharmaceutical and biotechnology research and development. Many leading pharmaceutical companies and research institutions in the region focus on rare diseases, including acquired orphan blood diseases. This concentration of expertise and resources drives innovation and the development of new therapies. The United States has well-established regulatory agencies, such as the U.S. Food and Drug Administration (FDA), that have implemented orphan drug designations and fast-track approval processes for rare disease therapies. These regulatory incentives have encouraged pharmaceutical companies to invest in orphan disease research and development. The North American market, including the United States and Canada, is substantial in terms of both population and healthcare spending. This creates a sizable market for orphan disease therapeutics, attracting investments and driving market growth. North America boasts advanced healthcare infrastructure and facilities, which enable the diagnosis and treatment of rare diseases, including acquired orphan blood diseases. Access to specialized medical centers and expertise is crucial for patients with these conditions.

Key Market Players

Alexion Pharmaceuticals, Inc.

Amgen, Inc.

Celgene Corporation

Eli Lilly and Company

Sanofi S.A.

GlaxoSmithKline plc,

Cyclacel Pharmaceuticals, Inc.

Onconova Therapeutics, Inc.

Incyte Corporation,

CTI BioPharma Corp

Report Scope:

In this report, the Global Acquired Orphan Blood Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acquired Orphan Blood Diseases Therapeutics Market, By Therapy:

• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By Disease Indication:

• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Acquired Orphan Blood Diseases Therapeutics Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Acquired Orphan Blood Diseases Therapeutics Market.

Available Customizations:

• Global Acquired Orphan Blood Diseases Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, Others)
  • 5.2.2. By Disease Indication (Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
  • 5.2.4. By Company (2022)
• 5.3. Market Map

6. Asia Pacific Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Disease Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. India Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Australia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Japan Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapy
      • 6.3.4.2.2. By Disease Indication
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. South Korea Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapy
      • 6.3.5.2.2. By Disease Indication
      • 6.3.5.2.3. By Distribution Channel

7. Europe Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Disease Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Spain Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. United Kingdom Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By Distribution Channel

8. North America Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Disease Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Mexico Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Canada Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Distribution Channel

9. South America Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Disease Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Disease Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Acquired Orphan Blood Diseases Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Alexion Pharmaceuticals, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Amgen, Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Celgene Corporation
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Eli Lilly and Company
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Sanofi SA
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. GlaxoSmithKline plc
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Cyclacel Pharmaceuticals Inc.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Onconova Therapeutics, Inc
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Incyte Corporation
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. CTI BioPharma Corp
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer